28 / 46
[Others -> discussion] [BMk+]
Q
P
Trial arm
2006200720082009201020112012201320142015201620172018201920202021202220232024
SOC+metformin
K
K
SOC+tE2
L
L
SOC+rucaparib [BMk+]
M
M
[Others -> discussion] [BMk+]
P
N
G
G
SOC+abi
B
B
SOC+zoledronic acid
C
C
SOC+docetaxel
D
D
SOC+celecoxib
E
E
SOC+zoledronic acid+docetaxel
F
F
SOC+zoledronic acid+celecoxib
A
A
Standard-of-care (SOC) = ADT (+/-RT)
H
H
SOC+M1|RT {M1}
J
J
SOC+enz+abi
(+/-docetaxel)
molecular resource
Tumour blocks, blood spots and saliva – ongoing. Target 1600 patients.
Tumour blocks, saliva and sequential plasma – ongoing. Target 1000 patients.
Tumour blocks, saliva and sequential plasma analysed
prior
to randomisation. Planned.